Selective small molecules blocking HIV-1 Tat and coactivator PCAF association

Area of Science:

• Molecular Biology
• Virology
• Drug Discovery

Background:

• Drug resistance in HIV treatment arises from mutations in viral proteins, leading to persistent viral production and immune dysfunction.
• Targeting host cell proteins essential for viral replication, instead of viral proteins, offers a strategy to mitigate drug resistance.
• HIV protease inhibitors have faced challenges due to the development of viral drug resistance.

Purpose of the Study:

• To develop a novel class of compounds targeting host cell factors involved in HIV replication.
• To investigate a structure-based approach for designing inhibitors of the bromodomain of PCAF.
• To assess the potential of inhibiting PCAF-Tat interaction for controlling HIV transcription and replication.

Main Methods:

• Structure-based drug design was employed to develop N1-aryl-propane-1,3-diamine compounds.
• The compounds were designed to selectively inhibit the bromodomain of PCAF (p300/CBP-associated factor).
• The study focused on the essential association between PCAF and the HIV trans-activator Tat.

Main Results:

• A novel class of N1-aryl-propane-1,3-diamine compounds was successfully developed.
• These compounds selectively inhibit the bromodomain of the human transcriptional co-activator PCAF.
• The inhibition targets the PCAF-Tat interaction, crucial for HIV transcription and replication.

Conclusions:

• The developed compounds represent a promising new class of potential therapeutics for HIV.
• Targeting the PCAF bromodomain offers a novel strategy to combat HIV, potentially overcoming drug resistance.
• This approach highlights the potential of targeting host cell proteins in antiviral therapy.